Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > BUSINESS
BUSINESS
- US FDA Accepts Rexulti sNDA for Alzheimer’s Agitation: Otsuka/Lundbeck
January 11, 2023
- Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy
January 11, 2023
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
- AnGes, miRaX Ink Option Pact for MicroRNA Research
January 11, 2023
- Forxiga Now Available for Heart Failure Regardless of LVEF
January 11, 2023
- AbbVie, Eisai to End Humira Copromotion in June
January 11, 2023
- Japan Ethical Drug Sales Up 2.1% in November: Crecon
January 11, 2023
- Official Margin Proposal Only Realistic for Partial Introduction: Crecon President
January 10, 2023
- Top-Tier Pharma Companies, Mid-Sized Peers Mixed on Special PMP Step: New Year Confab
January 10, 2023
- Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
- Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
- Takeda’s TAK-755 Shows Promising PIII Interim Data for Ultra-Rare Blood Clotting Disorder
January 10, 2023
- Kaken Earns Japan Rights to CAH Med, Poised to Boost Rare Disease Biz
January 10, 2023
- Nippon Shinyaku Launches Open Innovation-Driven Drug Discovery Hub in US
January 10, 2023
- Fujifilm US Subsidiary Licenses iPSC Platform to Novo
January 10, 2023
- US Federal Circuit Nixes Lexiscan Patent Infringement, Astellas to File Appeal
January 6, 2023
- Dayvigo Tops HP Ranking, Twymeeg Most Promoted in GP Market 5 Months Running in November: Intage
January 6, 2023
- Shionogi Reports 2 Serious Side Effect Cases in Xocova Update
January 6, 2023
- Xocova Filed for Conditional Approval in South Korea
January 6, 2023
- Enhertu’s Application for NSCLC Use Accepted in Europe: Daiichi Sankyo
January 6, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…